Phase 2a Study of HPG1860 in Subjects With NASH
| Condition | NASH - Nonalcoholic Steatohepatitis |
|---|---|
| Phase | Phase 2 |
| Sponsor | Hepagene (Shanghai) Co., Ltd. |
| Status | Completed |
| Enrollment | 89 participants |
| Interventions | HPG1860 |
| Start date | Nov 22, 2021 |
| Completion date | Feb 28, 2023 |
| Results posted | May 28, 2026 |
Summary
This is a Phase 2a, randomized, double-blind, placebo-controlled, parallel group, multiple arm, multicenter study of 3 different doses of HPG1860 versus placebo in subjects with biopsy-confirmed or phenotypic NASH.
Safety and Tolerability of Treatment
| Placebo | 12 Participants |
|---|---|
| HPG1860 3 mg | 13 Participants |
| HPG1860 5 mg | 13 Participants |
| HPG1860 8 mg | 18 Participants |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatoh — Akero Therapeutics, Inc
- Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Va — Galectin Therapeutics Inc.
- Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease — Wake Forest University Health Sciences
- Effect of Obesity on Proton Pump Inhibitors — Children's Mercy Hospital Kansas City
- Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatoti — Merck Sharp & Dohme LLC
- Vitamin E Dosing Study — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)